Drugs / Human primary Retinal Pigment Epithelial (HuRPE) cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03566147 | Aug 2018 → Dec 2019 | Leber congenital amaurosis | Eyecure Therapeutics Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human primary Retinal Pigment Epithelial (HuRPE) cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03566147 ↗ |
| Known as | HuRPE | “Human primary Retinal Pigment Epithelial (HuRPE) cells” NCT03566147 ↗ |
| Route | Other | “administered into the subretinal space” NCT03566147 ↗ |